Skip to Content
Søk Menu

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

Marco Donia moderated a press conference on immunotherapy at ESMO 2024. In this MEDtalk, he discusses significant updates on neoadjuvant treatments for stage 3 melanoma, where immunotherapy before surgery improves outcomes, mainly when a significant pathological response is achieved.
Marco Donia

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynekologisk cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungcancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynekologisk cancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungcancer
Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Levercancer Play the Video 04:57
Back to top